Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Jenscare Scientific Co. Ltd. Class H ( (HK:9877) ) just unveiled an update.
Jenscare Scientific Co., Ltd. announced the release of clinical study results for its multi-product portfolio at the TCT 2025 conference in San Francisco. The studies, including the LuX-Valve Plus TRINITY, JensClip, and Ken-Valve, demonstrated high success rates and significant improvements in patient outcomes, positioning the company as a leader in transcatheter cardiovascular therapies. The LuX-Valve Plus TRINITY study, in particular, showed a 97% device success rate and notable enhancements in patients’ quality of life, underscoring the safety and efficacy of Jenscare’s products for stakeholders.
More about Jenscare Scientific Co. Ltd. Class H
Jenscare Scientific Co., Ltd. is a company based in the People’s Republic of China, specializing in the development of transcatheter heart valve replacement and repair systems. The company focuses on innovative cardiovascular solutions, targeting high-risk patients with severe heart valve conditions.
Average Trading Volume: 677,309
Technical Sentiment Signal: Buy
Current Market Cap: HK$5.85B
See more data about 9877 stock on TipRanks’ Stock Analysis page.